HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Comparative analysis of organ-specific autoantibodies and celiac disease--associated antibodies in type 1 diabetic patients, their first-degree relatives, and healthy control subjects.

AbstractOBJECTIVE:
In type 1 diabetes the coexistence with other endocrine diseases and organ-specific autoantibodies has been frequently reported leading to the concept of autoimmune polyendocrine syndrome (APS). In addition, an association of type 1 diabetes with celiac disease has been described. These disorders share a similar genetic background, and first-degree relatives of type 1 diabetic patients may also be affected significantly. Screening for specific antibodies allows early diagnosis of these disorders.
RESEARCH DESIGN AND METHODS:
In the present cross-sectional study, we analyzed sera from 197 recent-onset type 1 diabetic patients at the time of diagnosis, 882 first-degree relatives, and sera of 150 healthy control subjects for prevalence and co-occurence of the following antibodies (method): insulin autoantibodies (radioimmunoassay); GAD and IA-2 antibodies (radioligand assay); islet cell antibody, anti-adrenal cortex antibodies, and anti-gastric parietal cell antibodies (indirect immunofluorescence); anti-thyroglobulin and anti-thyroid peroxidase antibodies; and gliadin IgG/A and tissue-transglutaminase IgA (enzyme-linked immunosorbent assay).
RESULTS:
The overall frequency of gastric patietal cell antibodies and adrenal antibodies did not differ significantly among groups. In contrast, type 1 diabetes-associated antibodies and thyroid antibodies were significantly more frequent both in recent-onset type 1 diabetic patients and in the group of first-degree relatives (P < 0.05). The prevalence of gliadin IgG/IgA and transglutaminase IgA was significantly higher in the group of recent-onset type 1 diabetic patients (P < 0.05), but the difference between first-degree relatives and control subjects did not reach statistical significance. Focusing on the coexistence of antibodies, the group of recentonset type 1 diabetic patients presented with 27.4% of the subjects testing antibody-positive-specific for two or more of the envisaged disorders (i.e., type 1 diabetes, autoimmune thyroiditis, and celiac disease) compared with 3.1% in the group of first-degree relatives and 0 of 150 in the control population (P < 0.05).
CONCLUSIONS:
We conclude that, in an active case-finding strategy, recent-onset type 1 diabetic patients should be routinely screened at least for concomitant autoimmune thyroid disease and additionally for celiac disease. Screening in their first-degree relatives should include at a minimum the search for thyroid autoimmunity in addition to screening for pre-type 1 diabetes.
AuthorsC Jaeger, E Hatziagelaki, R Petzoldt, R G Bretzel
JournalDiabetes care (Diabetes Care) Vol. 24 Issue 1 Pg. 27-32 (Jan 2001) ISSN: 0149-5992 [Print] United States
PMID11194235 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Autoantibodies
  • Autoantigens
  • HLA-D Antigens
  • Insulin
  • Isoenzymes
  • Gliadin
  • Thyroglobulin
  • Iodide Peroxidase
  • Transglutaminases
  • Glutamate Decarboxylase
  • glutamate decarboxylase 2
Topics
  • Adolescent
  • Adrenal Cortex (immunology)
  • Adult
  • Autoantibodies (blood)
  • Autoantigens (immunology)
  • Celiac Disease (immunology)
  • Child
  • Child, Preschool
  • Cross-Sectional Studies
  • Diabetes Mellitus, Type 1 (genetics, immunology)
  • Female
  • Gliadin (immunology)
  • Glutamate Decarboxylase (immunology)
  • HLA-D Antigens (immunology)
  • Humans
  • Insulin (immunology)
  • Iodide Peroxidase (immunology)
  • Islets of Langerhans (immunology)
  • Isoenzymes (immunology)
  • Male
  • Middle Aged
  • Parietal Cells, Gastric (immunology)
  • Thyroglobulin (immunology)
  • Transglutaminases (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: